Basal cell carcinomas, the most common form of skin cancer, typically appear in sun-exposed areas like the face. Treating locally advanced tumors, especially those that are difficult to remove surgically, can be a challenge. However, a recent study conducted by a research team from MedUni Vienna and University Hospital Vienna has shown promising results with a new therapy approach.
The study focused on the use of Talimogene Laherparepvec (TVEC), an active substance that led to a reduction in the size of basal cell carcinomas in all participants. This not only improved the surgical removal process but also resulted in complete tumor regression in some patients. The findings of this study were published in the journal Nature Cancer.
TVEC, a genetically modified herpes simplex virus, is currently approved for treating superficial melanoma metastases. The virus targets and destroys tumor cells while activating the immune system simultaneously. The goal of the study was to shrink the tumor before surgery to minimize any functional or cosmetic issues post-procedure. A total of 18 patients with basal cell carcinoma received six injections of TVEC over 13 weeks before undergoing surgical tumor removal.
Principal investigator Christoph Höller, Head of the Skin Tumor Centre at the Department of Dermatology, summarized the results, stating that half of the patients saw a significant reduction in tumor size, allowing for direct wound closure during surgery. In one-third of cases, histological examination revealed no remaining tumor cells. Overall, all treated tumors decreased in size, with no tumor progression noted during therapy. Patients also reported tolerating the treatment well.
Lead author Julia Ressler, also from the Department of Dermatology, emphasized that this new treatment option not only simplifies surgical procedures but also helps avoid disfiguring operations and functional limitations. Analysis conducted in collaboration with St. Anna Children’s Hospital revealed strengthened immune responses within tumor tissues during TVEC therapy.
The study indicates that TVEC could be a valuable neoadjuvant treatment option for basal cell carcinoma, particularly in patients who should avoid extensive surgery. Further research is planned to validate the benefits of this approach in a larger patient population.
For more information on this study, refer to the article “Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)” published in Nature Cancer. Additional studies are underway to confirm the advantages of this innovative treatment option.
This research was conducted by the Medical University of Vienna and offers a promising outlook for individuals battling basal cell carcinoma. Stay updated with the latest developments in skin cancer treatment by visiting the Medical University of Vienna’s website.
